"Multiple Myeloma Therapeutics - Pipeline Assessment and Market Forecasts to 2017" Published

Jan. 16, 2011 - PRLog -- GlobalData, the industry analysis specialist, has released its new report, "Multiple Myeloma Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global multiple myeloma (MM) therapeutics market. The report identifies the key trends shaping and driving the global MM therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global MM sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The global MM (MM) market was valued at $2,347m in 2009 and is forecast to grow at a CAGR of 10.4% for the next seven years, to reach $5,185m by 2017. The growth will primarily be driven by an increase in the disease incidence rate, an increase in awareness of the treatment options, an increase in the treatment seeking population, and the acceptance of the existing therapies.

Scope

The scope of the report includes:

* Annualized global Multiple Myeloma therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
* Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
* Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include enzyme inhibitors, nonansamycin Hsp90 inhibitor, CDK inhibitors, proteosome inhibitors, immunomodulatory agents and apoptosis inducers.
* Analysis of the current and future market competition in the global MM therapeutic market. The key future market players covered are Bristol-Myers Squibb, Merck & Co., Inc., Celegene, Cephalon, Keryx Biopharmaceuticals, AB Science, Novartis AG, and Onyx Therapeutics.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
* Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the MM market.


Reasons to buy

The report will enhance your decision making capability. It will allow you to:

* Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
* Develop business strategies by understanding the trends shaping and driving the global MM therapeutics market.
* Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global MM therapeutics market in the future.
* Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
* Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
* Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
* What's the next big thing in the global MM therapeutics market landscape? Identify, understand and capitalize.



For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/109113_multiple_myeloma_therap...


Partial Table of Contents:

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Multiple Myeloma Therapeutics: Introduction 5
2.1 Multiple Myeloma Staging System: 5
2.1.1 The Durie-Salmon System (D-S): 5
2.1.2 The International Staging System (ISS) 6
3 Multiple Myeloma Therapeutics: Market Characterization 7
3.1 Overview 7
3.2 Multiple Myeloma Market Size 7
3.3 Multiple Myeloma Market Forecast and Compound Annual Growth Rate 7
3.4 Drivers and Barriers for the Multiple Myeloma Market 9
3.4.1 Drivers for the Multiple Myeloma Market 9
3.4.2 Barriers for the Multiple Myeloma Market 10
3.5 Opportunity and Unmet Need 10
3.6 Key Takeaway 11
4 Multiple Myeloma Therapeutics: Competitive Assessment 12
4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Product Profile for the Major Marketed Products in the Multiple Myeloma Market 13
4.3.1 Velcade (bortezomib) with Melphalan and Prednisone 13
4.3.2 Revlimid (lenalidomide) with Dexamethasone 15
4.3.3 Thalomid (thalomide) with Dexamethasone 17
4.3.4 Doxil (doxorubicin HCl liposome injection) with Bortezomib 18
4.3.5 Mozobil (plerixafor injection) with G-CSF (Granulocyte colony-stimulating factor) 20
4.4 Key Take Away 21
5 Multiple Myeloma Therapeutics: Pipeline Assessment 22
5.1 Overview 22
5.2 Strategic Pipeline Assessment 22
5.3 Multiple Myeloma Market - Promising Drugs under Clinical Development 23
5.4 Molecule Profile for Promising Drugs under Clinical Development 24
5.4.1 Pomalidomide (Actimid, CC-4047) 24
5.4.2 Safety 24
5.4.3 Carfilzomib 24
5.4.4 Perifosine (KRX-0401) 25
5.4.5 BHQ880 25
5.5 Multiple Myeloma Market - Clinical Pipeline by Mechanism of Action 27
5.5.1 Multiple Myeloma - Phase III Clinical Pipeline 28
5.5.2 Multiple Myeloma Market - Phase II Clinical Pipeline 29
5.5.3 Multiple Myeloma Market - Phase I Clinical Pipeline 30
5.5.4 Multiple Myeloma Market - Preclinical Pipeline 31
5.5.5 Multiple Myeloma Market - Discovery Pipeline 31
5.6 Key Takeaway 32
6 Multiple Myeloma Therapeutics: Implications for Future Market Competition 32
7 Multiple Myeloma Therapeutics: Future Players in the Multiple Myeloma Market 33
7.1 Introduction 33
7.2 Novartis AG 34
7.2.1 Overview 34
7.2.2 Business Description 34
7.3 Merck & Co., Inc. 35
7.3.1 Overview 35

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1091...

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.  View more research from GlobalData at http://www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.